Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Nasdaq VYNE BridgeBio Bristol Myers FDA Food and Drug Administration Lexaria BridgeBio Pharma Bristol Myers Squibb NYSE
  • Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume of 8.06 million shares, closed regular trading session at $74.86.
  • Rani Therapeutics (NASDAQ:RANI) announced positive topline results from the single-ascending dose (SAD) portion of its Phase 1 clinical study of its lead asset RT-102 for the potential treatment of osteoporosis. Rani Therapeutics shares traded in a range of $11.03 to $11.51 on a day volume of 13.93 thousand shares, closed regular trading session at $11.10. The company shares are currently trading at $10.75, down 3.2 percent in the after-hours trading session.
  • The U.S. Food and Drug Administration (FDA) has announced 510(k) clearance to ReShape Lifesciences’ (NASDAQ:RSLS) Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and bariatric surgical procedures. ReShape shares traded in a range of $0.44 to $0.8 on a day volume of 11.26 million shares, closed regular trading session at $0.45.
  • BridgeBio Pharma (NASDAQ:BBIO) and Sentynl Therapeutics  announced that the State of Israel Ministry of Health has approved NULIBRY (fosdenopterin) for Injection as the first therapy in Israel to treat MoCD Type A with the indication to reduce the risk of mortality for patients with molybdenum cofactor deficiency (MoCD) Type A. BridgeBio shares traded in a range of $11.1 to $12.21 on a day volume of 2.04 million shares, closed regular trading session at $11.99.
  • Lexaria Bioscience (NASDAQ:LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting regarding DehydraTECH-CBD for the treatment of hypertension. Lexaria shares traded in a range of $2.72 to $2.96 on a day volume of 89.16 thousand shares, closed regular trading session at $2.87.
  • VYNE Therapeutics (NASDAQ:VYNE) announced results from the Phase 2a segment of a Phase 1b/2a clinical trial evaluating FMX114 for the treatment of mild-to-moderate atopic dermatitis (AD). VYNE shares traded in a range of $0.26 to $0.34 on a day volume of 4.75 million shares, closed regular trading session at $0.31.
  • LianBio (NASDAQ:LIAN) announced the completion of enrollment in the Phase 3 EXPLORER-CN clinical study of mavacamten in Chinese patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), expect to report topline results in mid-2023. LianBio shares traded in a range of $2.41 to $2.86 on a day volume of 572.39 thousand shares, closed regular trading session at $2.7.
  • TRACON Pharmaceuticals (NASDAQ:TCON) announced that the Independent Data Monitoring Committee for the ENVASARC pivotal trial has recommended that the trial proceed as planned following the review of three week safety data from more than 20 patients enrolled into the trial. TRACON shares traded in a range of $1.83 to $2.15 on a day volume of 167.43 thousand shares, closed regular trading session at $2.07. The company shares are currently trading at $2.15, up 3.86 percent in the after-hours trading session.
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Middle children are more cooperative than their siblings, study suggests
After decades of debate, one of the largest ever studies on birth order suggests it does actually make a difference
The Guardian - UK
The Guardian - UK
Work or play? The rise of online ‘kidfluencers’ is raising complex legal and ethical questions
Videos of children opening boxes of toys and playing with them have become a feature of online marketing – making stars out of children as young as two.
The Conversation
The Conversation
She's here for 'a kitchen pep talk' during the holiday whirlwind
If you’re feeling too overwhelmed to cook during the holidays, maybe a new book by Margaret Eby can help
The Independent UK
The Independent UK
All the celebrities that have supported Blake Lively after Justin Baldoni lawsuit
Lively has received a huge amount of support after filing the lawsuit against Baldoni
The Independent UK
The Independent UK
Where’s Santa? Here’s how to track his journey this Christmas Eve
NORAD’s Santa Tracker website launched this year on December 1
The Independent UK
The Independent UK
Gen Z’s politics are hard to categorize – and a harbinger of a new political order
The great clashes to come will be less between left and right than between those inside and outside a dying establishment
The Guardian - US
The Guardian - US
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
Download on the AppStore Get it on Google Play